In a recent transaction, John P. Hamill, the Senior Vice President, Chief Financial Officer, and Principal Financial (NASDAQ:PFG) and Accounting Officer of Aprea Therapeutics, Inc. (NASDAQ:APRE), purchased 450 shares of the company's common stock. The shares were acquired on October 10, 2024, at a weighted average price of $2.61 per share, totaling approximately $1,174.
The purchase was carried out in multiple transactions, with prices ranging from $2.55 to $2.618 per share. Following this acquisition, Hamill now directly owns 19,318 shares of Aprea Therapeutics.
This move by a key executive comes as part of a broader strategy to increase personal investment in the company, signaling confidence in Aprea Therapeutics' future prospects.
InvestingPro Insights
The recent insider purchase by John P. Hamill, CFO of Aprea Therapeutics, Inc. (NASDAQ:APRE), takes on added significance when viewed through the lens of the company's current financial position. According to InvestingPro data, Aprea's market capitalization stands at a modest $13.91 million, reflecting its status as a small-cap biopharmaceutical company.
Despite the CFO's show of confidence, InvestingPro Tips highlight some challenges facing the company. Aprea is "quickly burning through cash" and "suffers from weak gross profit margins." These factors may explain why the stock has "taken a big hit over the last six months," with a price total return of -56.61% during that period.
On a positive note, InvestingPro Tips indicate that Aprea "holds more cash than debt on its balance sheet" and "liquid assets exceed short term obligations." These factors could provide some financial flexibility as the company navigates its current challenges.
The company's revenue growth is a bright spot, with a remarkable 410.91% increase over the last twelve months as of Q2 2024. However, this growth hasn't translated to profitability yet, as Aprea is "not profitable over the last twelve months" according to InvestingPro Tips.
For investors considering Aprea, it's worth noting that analysts at InvestingPro have set a fair value target of $16 per share, significantly higher than the current trading price. However, given the company's financial challenges, potential investors should carefully weigh the risks and opportunities.
InvestingPro offers 11 additional tips for Aprea Therapeutics, providing a more comprehensive analysis for those interested in delving deeper into the company's prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.